MedTrace Logo

Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)

NCT00727298 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4485

Last updated 2015-12-01

Study results available
· View outcomes & findings →

Summary

This study will be performed to evaluate and document the safety and efficacy of infliximab (Remicade®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice of rheumatologists, gastroenterologists, and dermatologists.

Conditions

Interventions

BIOLOGICAL

Infliximab

Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2011-08-31
Completion
2011-08-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00727298 on ClinicalTrials.gov